Jing Tong Tan

BACKGROUND: Whether glycemic control influences the risk of colonic adenoma and colorectal cancer (CRC) development is unknown…

BACKGROUND: Epidemiological data on the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and hepatocellular carcinoma (HCC) are limited. We aimed to investigate the association of SGLT-2i use with HCC and hepatic decompensation in patients with diabetes mellitus (DM)…

BACKGROUND AND AIM: We aimed to compare efficacy of vonoprazan-based therapies and bismuth-based quadruple therapy as first-line treatment for _Helicobacter pylori_ (_H. pylori_) infection in Southern China, where high primary resistance rates of clarithromycin and levofloxacin (>30%) exist…

BACKGROUND: While sodium-glucose cotransporter 2 inhibitors improves cardiovascular and renal outcomes irrespective of diabetes mellitus (DM) status, their effects in metabolic-dysfunction associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM) are unknown…